| Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

2024 Tampa Patient and Family Conference

Registration is open for the Tampa, FL, Patient and Family Conference.  Please join your peers and bone marrow failure experts for this opportunity!

Event Date: 
Sat, 10/19/2024 - 7:30am (EDT)
Conference Event Type: 

2024 Philiadelphia, PA, Patient and Family Conference

The conference will occur over two days - Friday, July 19 from 2-7 PM ET and Saturday, July 20 from 8AM - 4 PM ET.

This conference will provide sessions for both adults and children.

At the hotel, parking is valet only and paid by AAMDSIF.

Conference location - The Inn at Penn @ 3600 Sansome Street Philadelphia, PA 19104

Event Date: 
Fri, 07/19/2024 - 2:00pm (EDT) to Sat, 07/20/2024 - 4:00pm (EDT)
Conference Event Type: 

2024 Chicago Patient and Family Conference

Register now for the 2024 Patient and Family Conference, held in partnership with the University of Chicago.

Event Date: 
Sat, 09/14/2024 - 7:30am (EDT)
Conference Event Type: 

2024 Seattle Patient and Family Conference

The time is now to save your seat for the 2024 Patient and Family Conference in Los Angeles!

Plan to attend on June 22, 2024, in Seattle, WA, in partnership with Fred Hutchinson Cancer Center - Register Here

Conference Location: Fred Hutchinson Cancer Research Center Weintraub Building 1100 Fairview Ave N Seattle, WA 98109
Parking: There is parking in front of the Weintraub Building. 

Register for the 2024 Seattle Patient and Family Conference
Event Date: 
Sat, 06/22/2024 - 7:45am (EDT)
Conference Event Type: 

2024 Los Angeles Patient and Family Conference

The time is now to save your seat for the 2024 Patient and Family Conference in Los Angeles!

Plan to attend on April 13, 2024, in Los Angeles, CA, in partnership with City of Hope (Duarte, CA) - Register Here

Register Now for the 2024 Los Angeles Patient and Family Conference
Event Date: 
Sat, 04/13/2024 - 7:45am (EDT)
Conference Event Type: 

Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy

Author(s): 
Avenoso D, Serpenti F, Slonim LB, Bouziana S, Dazzi F, Hannah G, Kenyon M, Mehra V, Kulasekararaj A, Krishamurthy P, Shah MN, Lionel S, Pagliuca A, Potter V
Primary Author: 
Avenoso D
Journal Title: 
Mediterranean Journal of Hematology and Infectious Diseases
Original Publication Date: 
Jan 2024

Background: Allogeneic haematopoietic stem-cell transplant is an option, potentially curative, for high-risk acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients. Post-transplant cyclophosphamide administration allows for the selection of haploidentical donors in patients who are eligible for the procedure but do not have a fully matched donor since it can overcome the HLA barrier.

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Author(s): 
Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U
Primary Author: 
Zeidan AM
Journal Title: 
Lancet Hematology
Original Publication Date: 
Jan 2024

Background: Sabatolimab is an immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), an immuno-myeloid regulator expressed on immune cells and leukaemic

Bone Marrow Disease(s): 

Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Author(s): 
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE
Primary Author: 
Garcia-Manero G
Journal Title: 
Lancet Hematology
Original Publication Date: 
Jan 2024

Background: The DNA methyltransferase inhibitors azacitidine and decitabine for individuals with

Bone Marrow Disease(s):